Pre‐eclampsia screening and prevention: Implementing FIGO guidelines in a Thai population

OBJECTIVE: To evaluate the real-world implementation, screening performance, aspirin uptake, and safety of a FIGO (the International Federation of Gynecology & Obstetrics)-based first-trimester pre-eclampsia screening and prevention program. METHODS: This retrospective cohort study included women initiating antenatal care before 14 weeks of gestation at a tertiary referral center in southern Thailand from 2021 to 2024. Screening incorporated maternal factors, mean arterial pressure, and uterine artery pulsatility index. Women with a calculated risk of 1:100 or greater were classified as being at high risk and offered aspirin 162 mg nightly. Outcomes included screening coverage, detection rates, aspirin uptake, pregnancy outcomes, and bleeding complications. RESULTS: Among 1713 pregnancies, 71 developed pre-eclampsia (4.1%), including 49 with severe features. Overall, 1106 women were screened (64.6%), but coverage reached 93.6% by the end of implementation. The screen-positive rate was 11.3%. Detection rates were 61.7% for overall pre-eclampsia, 69.6% for delivery before 37 weeks of gestation, 87.5% for delivery before 34 weeks of gestation, and 100% for delivery before 32 weeks of gestation, with false-positive rates of approximately 9%-11%. Aspirin uptake among screen-positive women was 99.2%. Pre-eclampsia was associated with higher rates of cesarean delivery, preterm birth, lower birth weight, and neonatal intensive care unit admission. No eclampsia, placental abruption, maternal intensive care unit admission, maternal death, stillbirth, or neonatal death occurred. After adjustment for potential confounders, aspirin was not associated with the risk of an estimated blood loss of 500 mL or more, and the risk of an estimated blood loss of 1000 mL or more did not differ significantly between groups. CONCLUSION: FIGO-based first-trimester screening was feasible in routine care, with increasing coverage as implementation matured, near-universal aspirin uptake, and clinically useful detection of preterm pre-eclampsia. Aspirin use was not significantly associated with severe bleeding.

Authors

Institutions

Publication Details

Journal
International Journal of Gynecology & Obstetrics
Published
2026-11-16
DOI
https://doi.org/10.1002/ijgo.71503
Primary Topic
Pregnancy and preeclampsia studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pre‐eclampsia screening and prevention: Implementing FIGO guidelines in a Thai population

Alan Frederick Geater, Ninlapa Pruksanusak, Manaphat Suksai, Intouch Sophark et al.
International Journal of Gynecology & Obstetrics
Pregnancy and preeclampsia studies
article

Pre‐eclampsia screening and prevention: Implementing FIGO guidelines in a Thai population

Alan Frederick Geater, Ninlapa Pruksanusak, Manaphat Suksai, Intouch Sophark, Chitkasaem Suwanrath, Thitima Suntharasaj
article en

Abstract

OBJECTIVE: To evaluate the real-world implementation, screening performance, aspirin uptake, and safety of a FIGO (the International Federation of Gynecology & Obstetrics)-based first-trimester pre-eclampsia screening and prevention program. METHODS: This retrospective cohort study included women initiating antenatal care before 14 weeks of gestation at a tertiary referral center in southern Thailand from 2021 to 2024. Screening incorporated maternal factors, mean arterial pressure, and uterine artery pulsatility index. Women with a calculated risk of 1:100 or greater were classified as being at high risk and offered aspirin 162 mg nightly. Outcomes included screening coverage, detection rates, aspirin uptake, pregnancy outcomes, and bleeding complications. RESULTS: Among 1713 pregnancies, 71 developed pre-eclampsia (4.1%), including 49 with severe features. Overall, 1106 women were screened (64.6%), but coverage reached 93.6% by the end of implementation. The screen-positive rate was 11.3%. Detection rates were 61.7% for overall pre-eclampsia, 69.6% for delivery before 37 weeks of gestation, 87.5% for delivery before 34 weeks of gestation, and 100% for delivery before 32 weeks of gestation, with false-positive rates of approximately 9%-11%. Aspirin uptake among screen-positive women was 99.2%. Pre-eclampsia was associated with higher rates of cesarean delivery, preterm birth, lower birth weight, and neonatal intensive care unit admission. No eclampsia, placental abruption, maternal intensive care unit admission, maternal death, stillbirth, or neonatal death occurred. After adjustment for potential confounders, aspirin was not associated with the risk of an estimated blood loss of 500 mL or more, and the risk of an estimated blood loss of 1000 mL or more did not differ significantly between groups. CONCLUSION: FIGO-based first-trimester screening was feasible in routine care, with increasing coverage as implementation matured, near-universal aspirin uptake, and clinically useful detection of preterm pre-eclampsia. Aspirin use was not significantly associated with severe bleeding.

International Journal of Gynecology & Obstetrics
Prince of Songkla University (TH)
Pregnancy and preeclampsia studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon